Premium
Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia
Author(s) -
Das Prabodh,
Carcao Manuel,
Hitzler Johann
Publication year - 2006
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.20467
Subject(s) - medicine , lumbar puncture , recombinant factor viia , chemotherapy , intrathecal , fresh frozen plasma , coagulation , anesthesia , adverse effect , acute leukemia , coagulation testing , surgery , leukemia , platelet , cerebrospinal fluid
The persistence of abnormal coagulation test results after standard treatment with fresh frozen plasma (FFP) poses significant problems in children with acute leukemia requiring a diagnostic lumbar puncture and intrathecal chemotherapy. We report the prophylactic use of a single dose of 90 µg/kg recombinant activated factor VII (rFVIIa) in three children and the rapid correction of abnormal coagulation test results previously not corrected by FFP. Administration of rFVIIa was useful in avoiding a delay of diagnostic lumbar punctures and intrathecal chemotherapy. Hemorrhagic complications and adverse effects of rFVIIa were not observed. Prospective evaluation of this indication and dose appears warranted. © 2005 Wiley‐Liss, Inc.